Contemporary treatment of metastatic renal cell carcinoma
作者： Pawel Wiechno , Jakub Kucharz , Malgorzata Sadowska , Wojciech Michalski , Bozena Sikora-Kupis
关键词: Clinical trial 、 Angiogenesis 、 Medicine 、 Internal medicine 、 PI3K/AKT/mTOR pathway 、 Cabozantinib 、 Renal cell carcinoma 、 Immunotherapy 、 Pharmacology 、 Oncology 、 Targeted therapy 、 Nivolumab
摘要: … cell renal cell carcinoma. Approximately 20–30% of patients present initially with metastatic … Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous …
oncologyreviews.org
springer.com
core.ac.uk 
researchgate.net 参考文章(79)
Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante, Marc S. Ernstoff, Brian I. Rini, David F. McDermott, Jennifer J. Knox, Sumanta Kumar Pal, Martin Henner Voss, Padmanee Sharma, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, John F. Kurland, Paul Gagnier, Hans J. Hammers, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 32, pp. 5010- 5010 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.5010
Alan J. Korman, Karl S. Peggs, James P. Allison, Checkpoint blockade in cancer immunotherapy Advances in Immunology. ,vol. 90, pp. 297- 339 ,(2006) , 10.1016/S0065-2776(06)90008-X
Paul Cairns, Renal cell carcinoma Cancer Biomarkers. ,vol. 9, pp. 461- 473 ,(2011) , 10.3233/CBM-2011-0176
L Zhou, X-D Liu, M Sun, X Zhang, P German, S Bai, Z Ding, N Tannir, C G Wood, S F Matin, J A Karam, P Tamboli, K Sircar, P Rao, E B Rankin, D A Laird, A G Hoang, C L Walker, A J Giaccia, E Jonasch, Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma Oncogene. ,vol. 35, pp. 2687- 2697 ,(2016) , 10.1038/ONC.2015.343
Haoran Li, Haider Samawi, Daniel Y.C. Heng, The use of prognostic factors in metastatic renal cell carcinoma. Urologic Oncology-seminars and Original Investigations. ,vol. 33, pp. 509- 516 ,(2015) , 10.1016/J.UROLONC.2015.08.003
Anh Pham, Da-Wei Ye, Sumanta Pal, Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. Urologic Oncology-seminars and Original Investigations. ,vol. 33, pp. 517- 527 ,(2015) , 10.1016/J.UROLONC.2015.07.020
Carsten Grüllich, Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor Recent results in cancer research. ,vol. 201, pp. 207- 214 ,(2014) , 10.1007/978-3-642-54490-3_12
Toni K. Choueiri, VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives Current Clinical Pharmacology. ,vol. 6, pp. 164- 168 ,(2011) , 10.2174/157488411797189424
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
Margaret J Currie, Sarah P Gunningham, Kevin Turner, Cheng Han, Prudence AE Scott, Bridget A Robinson, Wen Chong, Adrian L Harris, Stephen B Fox, Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. The Journal of Pathology. ,vol. 198, pp. 502- 510 ,(2002) , 10.1002/PATH.1228